CiteFacts · FDA Drug Shortages · FDA source
Riluzole Oral Suspension
Status
FDA currently lists this ingredient in shortage.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Presentation | FDA availability field | FDA update |
|---|---|---|---|
| EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) | Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1) | Available | 08/17/2026 |
| EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) | Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1) | Available | 08/17/2026 |
| EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) | Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1) | Available | 08/17/2026 |
| EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) | Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1) | Unavailable | 08/17/2026 |
Source facts
Grouped generic ingredient: Riluzole Oral Suspension · 4 package records · Latest FDA row update: 08/17/2026
Therapeutic categories: Neurology
Dosage forms: Oral Suspension
Routes: ORAL
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-08-22T15:54:11+00:00. Derived grouping is documented in this record's derivations.